UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 544

Sortiert nach

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Annals of oncology, 2019-10, Vol.30 (10), p.1613-1621

2019

Volltextzugriff (PDF)

Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes

Journal of endocrinological investigation, 2024-03

2024

Volltextzugriff (PDF)

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

Leukemia, 2014-07, Vol.28 (7), p.1529-1536

2014

Volltextzugriff (PDF)

Antineoplastic drug occupational exposure: a new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive Buccal Micronucleus Cytome Assay biomarker

Toxicology letters, 2019-11, Vol.316, p.20-26

2019

Volltextzugriff (PDF)

Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations

European journal of cancer (1990), 2017-02, Vol.72, p.S167-S167

2017

Volltextzugriff (PDF)

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

HemaSphere, 2022-06, Vol.6 (Suppl), p.994-995

2022

Volltextzugriff (PDF)

Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e273-e273

2015

Volltextzugriff (PDF)

Will people change their vector-control practices in the presence of an imperfect dengue vaccine?

Epidemiology and infection, 2014-03, Vol.142 (3), p.625-633

2014

Volltextzugriff (PDF)

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

Annals of oncology, 2023-10, Vol.34, p.S623-S624

2023

Volltextzugriff (PDF)

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

The New England journal of medicine, 2008-07, Vol.359 (1), p.31-42

2008

Volltextzugriff (PDF)

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

The lancet oncology, 2013-04, Vol.14 (4), p.335-345

2013

Volltextzugriff (PDF)

ZIO-101 (S-dimethylarsino-glutathione): Phase I/II trials in advanced/progressive multiple myeloma

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.8109-8109

2007

Volltextzugriff (PDF)

1813 - Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations

European journal of cancer (1990), 2017-02, Vol.72, p.S167-S167

2017

Volltextzugriff (PDF)

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

Immuno-oncology technology, 2022-12, Vol.16, p.100307, Article 100307

2022

Volltextzugriff (PDF)

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

Annals of oncology, 2011-09, Vol.22 (9), p.2057-2067

2011

Volltextzugriff (PDF)

PRO3 SUCCESSOR STUDY: TREATMENT AND HEALTH CARE RESOURCE UTILIZATION BY SICKLE CELL PATIENTS WHO PARTICIPATED IN THE SUSTAIN STUDY IN THE UNITED STATES

Value in health, 2019-05, Vol.22, p.S335-S335

2019

Volltextzugriff (PDF)

A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.9133-9133

2007

Volltextzugriff (PDF)

Can biosimilars help achieve the goals of US health care reform?

Cancer management and research, 2017-01, Vol.9, p.197-205

2017

Volltextzugriff (PDF)

In response to Dr. Hicsonmez et al

International journal of radiation oncology, biology, physics, 2005-03, Vol.61 (4), p.1279-1279

Boccia, Ralph

2005

Volltextzugriff (PDF)

Relationship Between Initial Parenteral Iron Therapy Dosing and Treatment Effectiveness: A Real-World Retrospective Analysis

Journal of blood medicine, 2022-03, Vol.13, p.133-142

2022

Volltextzugriff (PDF)

Improved tolerability of amifostine with rapid infusion and optimal patient preparation

Seminars in oncology, 2002-12, Vol.29 (6 Suppl 19), p.9-13, Article asonc02906t0009

Boccia, Ralph

2002

Volltextzugriff (PDF)

Tecniche di aiuto alla decisione per la valutazione d'impatto ambientale: un'analisi comparata su di un caso di studio

Ce.S.E.T. Aestimum, 2009-06 (24)

R. Boccia

2009

Volltextzugriff (PDF)

6016 POSTER A novel organic arsenic S-dimethylarsino-glutathione (ZIO-101) experience in hematological malignancies

European journal of cancer supplements, 2007, Vol.5 (4), p.349-350

2007

Volltextzugriff (PDF)

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

Cancer management and research, 2015-01, Vol.7 (default), p.83-92

2015

Volltextzugriff (PDF)

PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)

HemaSphere, 2019-06, Vol.3 (S1), p.319-n/a

2019

Volltextzugriff (PDF)

1 – 25 von 544

Suche als RSS-Feed

Aktive Filter

KollektionPAIS Index

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(384)
Mit Volltextzugriff
(374)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(320)
Life Sciences & Biomedicine
(176)
Humans
(160)
Technology
(137)
Engineering
(125)
Engineering, Electrical & Electronic
(124)
Female
(103)
Male
(103)
Middle Aged
(78)
Adult
(65)
Biological And Medical Sciences
(62)
Aged
(56)
Medical Sciences
(49)
Oncology
(42)
Microwave Antennas
(38)
Risk Factors
(31)
Antennas
(30)
Microwave Measurement
(26)
Animals
(25)
Aged, 80 And Over
(23)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

Antineoplastic drug occupational exposure: a new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive Buccal Micronucleus Cytome Assay biomarker

Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL‐102)

Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) With Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results From a Phase 1b/2, Multicenter, Open-Label Study

Will people change their vector-control practices in the presence of an imperfect dengue vaccine?

1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

ZIO-101 (S-dimethylarsino-glutathione): Phase I/II trials in advanced/progressive multiple myeloma

1813 - Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations

195TiP A first-in-human, phase I a/b dose escalation and expansion study to evaluate RBS2418 as monotherapy and in combination with pembrolizumab in subjects with advanced unresectable, recurrent or metastatic tumors

A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer

PRO3 SUCCESSOR STUDY: TREATMENT AND HEALTH CARE RESOURCE UTILIZATION BY SICKLE CELL PATIENTS WHO PARTICIPATED IN THE SUSTAIN STUDY IN THE UNITED STATES

A phase II randomized, placebo-controlled, double-blind study of the efficacy and safety of RC-1291 (RC) for the treatment of cancer cachexia

Can biosimilars help achieve the goals of US health care reform?

In response to Dr. Hicsonmez et al

Relationship Between Initial Parenteral Iron Therapy Dosing and Treatment Effectiveness: A Real-World Retrospective Analysis

Improved tolerability of amifostine with rapid infusion and optimal patient preparation

Tecniche di aiuto alla decisione per la valutazione d'impatto ambientale: un'analisi comparata su di un caso di studio

6016 POSTER A novel organic arsenic S-dimethylarsino-glutathione (ZIO-101) experience in hematological malignancies

Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials

PF729 LONG‐TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM‐6, A REAL‐WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)

Aktive Filter

Suchergebnisse filtern